Background: Hormonal contraception (HC) is widely used throughout the world and has been associated with venous thrombosis (VT) such as deep vein thrombosis, pulmonary emboli, and cerebral VT. Objectives: To provide a current comprehensive overview of the risk of objectively confirmed VT with HC in healthy women compared to nonusers. Search methods: PubMed was searched from inception to April 2018 for eligible studies in the English language, with hand searching from past systematic reviews. Selection criteria: We selected original research evaluating risk of objectively confirmed VT in healthy women taking oral or nonoral HC compared with nonusers. Data collection: The primary outcome of interest was a fatal or nonfatal VT in users of HC compared to nonusers or past users. Studies with at least twenty events were eligible. Adjusted relative risks with 95 percent confidence intervals were reported. Three independent reviewers extracted data from selected studies. Results: 1,962 publications were retrieved through the search strategy, with 15 publications included. Users of oral contraception with levonorgesterol had increased risk of VT by a range of 2.79-4.07, while other oral hormonal preparations increased risk by 4.0-48.6. Levonorgestrel intrauterine devices did not increase risk. Etonogestrel/ethinyl estradiol vaginal rings increased the risk of VT by 6.5. Norelgestromin/ethinyl estradiol patches increased risk of VT by 7.9. Etonogestrel subcutaneous implants by 1.4 and depot-medroxyprogesterone by 3.6. The risk of fatal VT was increased in women aged fifteen to twenty-four by 18.8-fold. Conclusion: Users of HC have a significant increased risk of VT compared to nonusers. Current risks would project at least 300-400 healthy young women dying yearly in the United States due to HC. Women should be informed of these risks and offered education in fertility-awareness-based methods with comparable efficacy for family planning. Summary: HC is widely used throughout the world and has been associated with blood clots in the legs and lungs. We searched the literature and found the risks of currently used forms of birth control increased between three-and ninefold for blood clots for healthy women. The risks found would project 300-400 women dying from using HC each year in the United States.
Recent SARS-coV-2 subvariants (BQ.1.1, BA.2, BA.4, BA.5, collectively referred to as Omicron) are adept at evading the immune system but tend to be less severe with fewer hospitalizations and deaths. The incidence of bacterial co-infection at time of admission for SARS-COV-2 related illness early in the COVID pandemic was low. In 2022 when few relatively healthy patients were being admitted, we report three patients found to have bacterial co-infection with pneumococcal and staphylococcal species at time of hospital admission. Varying practices abound, including use of procalcitonin as a screening tool for bacterial coinfection in patients with SARS-coV-2 infection despite a recommendation against this practice in recent pneumonia treatment guidelines. In our cases the use of procalcitonin did not lead to antibiotic delay, however we propose a clinical support rule that can be utilized in the Emergency Department to more accurately guide empiric use of antibiotics in this patient population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.